Incidence of Significant Mitral Regurgitation in Acute Heart Failure Patients

Incidence of Significant Mitral Regurgitation in Patients Presenting With Acute Heart Failure: Journey to Tertiary Centre

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02728739

Acronym

MRAHF

Enrollment

500

Registered

2016-04-05

Start date

2016-06-06

Completion date

2018-02-28

Last updated

2018-02-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Heart Failure, Mitral Regurgitation

Brief summary

The purpose of this study is to determine the prevalence of moderate-to-severe Mitral Regurgitation (MR) in acute Heart Failure (HF) patients requiring hospital admission.

Detailed description

All patients admitted with symptoms of HF- (shortness of breath (SOB), peripheral oedema, palpitations and irregular heart beats) will be assessed by the Research Team. The level of BNP will be checked using a small device (i-STAT BNP) at the bedside. If results of the test suggest HF they will undergo special procedure called transthoracic echocardiography (TTE). TTE is an ultrasound scan of the heart which will enable the investigators' to grade severity of Mitral Regurgitation (MR) as well as strength of the heart muscle. The investigators will use bi-plane Simpton's method to calculate left ventricular (LV) ejection fraction (EF). Colour Doppler and PISA method will be used to quantify severity of MR or valve leak. Simultaneously there will be recording of heart sounds to find out if auscultation is reliable in identifying leaky valves.

Interventions

PROCEDURETransthoracic Echocardiogram (TTE) Assesment

Transthoracic Echocardiogram (TTE) will be carried out on all heart failure patients with elevated BNP level (\>30 pg/ ml) for grading of MR severity within 7 days.

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 100 Years

Healthy volunteers

Inclusion criteria

* Acute Heart Failure patients admitted to the Hospital * Elevated BNP level (\>30pg/ml)

Exclusion criteria

* Patients with BNP level (\< 30pg/ml)

Design outcomes

Primary

Measure	Time frame	Description
Grade 3 and above mitral regurgitation in acute heart failure.	12 months	TTE Grading is done on colour Doppler and proximal isovelocity surface area (PISA) method.

Secondary

Measure	Time frame	Description
Establish correlation between BNP level and severity of MR in acute HF	12 months	Standard statistical analysis of BNP level and grade of MR severity
The validity of Hospital Episode Statistics (HES) data against prevalence of grade 3-4 MR in the study.	12 month	Standard statistical analysis of 2 sets of data

Countries

United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 13, 2026